Cargando…
Real-Life Performance of F-18-FDG PET/CT in Patients with Cervical Lymph Node Metastasis of Unknown Primary Tumor
Background: Neoplasms in the head and neck region possess higher glycolytic activity than normal tissue, showing increased glucose metabolism. F-18-Flourodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) can identify an unknown primary tumor (CUP). Aim: The aim of this stu...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495705/ https://www.ncbi.nlm.nih.gov/pubmed/36140197 http://dx.doi.org/10.3390/biomedicines10092095 |
_version_ | 1784794084902174720 |
---|---|
author | Eilsberger, Friederike Noltenius, Friederike Elisabeth Librizzi, Damiano Wessendorf, Joel Luster, Markus Hoch, Stephan Pfestroff, Andreas |
author_facet | Eilsberger, Friederike Noltenius, Friederike Elisabeth Librizzi, Damiano Wessendorf, Joel Luster, Markus Hoch, Stephan Pfestroff, Andreas |
author_sort | Eilsberger, Friederike |
collection | PubMed |
description | Background: Neoplasms in the head and neck region possess higher glycolytic activity than normal tissue, showing increased glucose metabolism. F-18-Flourodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) can identify an unknown primary tumor (CUP). Aim: The aim of this study was to assess the real-life performance of F-18-FDG-PET/CT in detecting primary sites in patients with cervical lymph node metastasis of CUP. Methods: A retrospective data analysis of 31 patients who received FDG-PET/CT between June 2009 and March 2015 in a CUP context with histologically confirmed cervical lymph node metastasis was included. Results: In 48% of the patients (15/31), PET/CT showed suspicious tracer accumulation. In 52% of the patients (16/31), there was no suspicious radiotracer uptake, which was confirmed by the lack of identification of any primary tumor in 10 cases until the end of follow-up. FDG-PET/CT had a sensitivity of 67%, specificity of 91%, PPV of 92%, and NPV of 63% in detecting the primary tumor. Additionally, PET/CT showed suspicious tracer accumulation according to further metastasis in 32% of the patients (10/31). Conclusion: FDG-PET/CT imaging is a useful technique for primary tumor detection in patients in a cervical CUP context. Furthermore, it provides information on the ulterior metastasis of the disease. |
format | Online Article Text |
id | pubmed-9495705 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94957052022-09-23 Real-Life Performance of F-18-FDG PET/CT in Patients with Cervical Lymph Node Metastasis of Unknown Primary Tumor Eilsberger, Friederike Noltenius, Friederike Elisabeth Librizzi, Damiano Wessendorf, Joel Luster, Markus Hoch, Stephan Pfestroff, Andreas Biomedicines Article Background: Neoplasms in the head and neck region possess higher glycolytic activity than normal tissue, showing increased glucose metabolism. F-18-Flourodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) can identify an unknown primary tumor (CUP). Aim: The aim of this study was to assess the real-life performance of F-18-FDG-PET/CT in detecting primary sites in patients with cervical lymph node metastasis of CUP. Methods: A retrospective data analysis of 31 patients who received FDG-PET/CT between June 2009 and March 2015 in a CUP context with histologically confirmed cervical lymph node metastasis was included. Results: In 48% of the patients (15/31), PET/CT showed suspicious tracer accumulation. In 52% of the patients (16/31), there was no suspicious radiotracer uptake, which was confirmed by the lack of identification of any primary tumor in 10 cases until the end of follow-up. FDG-PET/CT had a sensitivity of 67%, specificity of 91%, PPV of 92%, and NPV of 63% in detecting the primary tumor. Additionally, PET/CT showed suspicious tracer accumulation according to further metastasis in 32% of the patients (10/31). Conclusion: FDG-PET/CT imaging is a useful technique for primary tumor detection in patients in a cervical CUP context. Furthermore, it provides information on the ulterior metastasis of the disease. MDPI 2022-08-27 /pmc/articles/PMC9495705/ /pubmed/36140197 http://dx.doi.org/10.3390/biomedicines10092095 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Eilsberger, Friederike Noltenius, Friederike Elisabeth Librizzi, Damiano Wessendorf, Joel Luster, Markus Hoch, Stephan Pfestroff, Andreas Real-Life Performance of F-18-FDG PET/CT in Patients with Cervical Lymph Node Metastasis of Unknown Primary Tumor |
title | Real-Life Performance of F-18-FDG PET/CT in Patients with Cervical Lymph Node Metastasis of Unknown Primary Tumor |
title_full | Real-Life Performance of F-18-FDG PET/CT in Patients with Cervical Lymph Node Metastasis of Unknown Primary Tumor |
title_fullStr | Real-Life Performance of F-18-FDG PET/CT in Patients with Cervical Lymph Node Metastasis of Unknown Primary Tumor |
title_full_unstemmed | Real-Life Performance of F-18-FDG PET/CT in Patients with Cervical Lymph Node Metastasis of Unknown Primary Tumor |
title_short | Real-Life Performance of F-18-FDG PET/CT in Patients with Cervical Lymph Node Metastasis of Unknown Primary Tumor |
title_sort | real-life performance of f-18-fdg pet/ct in patients with cervical lymph node metastasis of unknown primary tumor |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495705/ https://www.ncbi.nlm.nih.gov/pubmed/36140197 http://dx.doi.org/10.3390/biomedicines10092095 |
work_keys_str_mv | AT eilsbergerfriederike reallifeperformanceoff18fdgpetctinpatientswithcervicallymphnodemetastasisofunknownprimarytumor AT nolteniusfriederikeelisabeth reallifeperformanceoff18fdgpetctinpatientswithcervicallymphnodemetastasisofunknownprimarytumor AT librizzidamiano reallifeperformanceoff18fdgpetctinpatientswithcervicallymphnodemetastasisofunknownprimarytumor AT wessendorfjoel reallifeperformanceoff18fdgpetctinpatientswithcervicallymphnodemetastasisofunknownprimarytumor AT lustermarkus reallifeperformanceoff18fdgpetctinpatientswithcervicallymphnodemetastasisofunknownprimarytumor AT hochstephan reallifeperformanceoff18fdgpetctinpatientswithcervicallymphnodemetastasisofunknownprimarytumor AT pfestroffandreas reallifeperformanceoff18fdgpetctinpatientswithcervicallymphnodemetastasisofunknownprimarytumor |